EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 156 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,946,751 | -6.1% | 68,620 | -3.2% | 0.00% | -50.0% |
| Q4 2022 | $2,072,553 | +10.0% | 70,905 | -0.5% | 0.00% | +100.0% |
| Q3 2022 | $1,884,000 | -48.5% | 71,289 | -13.3% | 0.00% | -66.7% |
| Q2 2022 | $3,655,000 | -11.2% | 82,259 | -1.1% | 0.00% | 0.0% |
| Q1 2022 | $4,117,000 | -8.0% | 83,195 | -5.3% | 0.00% | 0.0% |
| Q4 2021 | $4,476,000 | -18.6% | 87,897 | -10.9% | 0.00% | -25.0% |
| Q3 2021 | $5,501,000 | +27.3% | 98,616 | -2.3% | 0.00% | +33.3% |
| Q2 2021 | $4,322,000 | -6.4% | 100,986 | -8.7% | 0.00% | 0.0% |
| Q1 2021 | $4,618,000 | -8.5% | 110,639 | +2.1% | 0.00% | -25.0% |
| Q4 2020 | $5,046,000 | +10.7% | 108,353 | +1.0% | 0.00% | 0.0% |
| Q3 2020 | $4,559,000 | +9.8% | 107,331 | +24.0% | 0.00% | 0.0% |
| Q2 2020 | $4,153,000 | +4.0% | 86,550 | -0.3% | 0.00% | 0.0% |
| Q1 2020 | $3,993,000 | -26.1% | 86,799 | -3.5% | 0.00% | -20.0% |
| Q4 2019 | $5,403,000 | +19.7% | 89,930 | +12.7% | 0.01% | +25.0% |
| Q3 2019 | $4,513,000 | -1.9% | 79,770 | -3.5% | 0.00% | 0.0% |
| Q2 2019 | $4,601,000 | +10.0% | 82,639 | -0.2% | 0.00% | 0.0% |
| Q1 2019 | $4,181,000 | +16.2% | 82,801 | -7.3% | 0.00% | 0.0% |
| Q4 2018 | $3,597,000 | -42.3% | 89,289 | -0.7% | 0.00% | -20.0% |
| Q3 2018 | $6,237,000 | +27.1% | 89,958 | +38.7% | 0.01% | 0.0% |
| Q2 2018 | $4,906,000 | +26.0% | 64,838 | -12.2% | 0.01% | +25.0% |
| Q1 2018 | $3,893,000 | +2.0% | 73,885 | +3.4% | 0.00% | 0.0% |
| Q4 2017 | $3,817,000 | -12.3% | 71,449 | -2.1% | 0.00% | 0.0% |
| Q3 2017 | $4,351,000 | -18.9% | 72,953 | +7.3% | 0.00% | -20.0% |
| Q2 2017 | $5,364,000 | +4.3% | 67,990 | +9.6% | 0.01% | -16.7% |
| Q1 2017 | $5,145,000 | +11.5% | 62,036 | +6.7% | 0.01% | 0.0% |
| Q4 2016 | $4,614,000 | +13.4% | 58,157 | +0.0% | 0.01% | +20.0% |
| Q3 2016 | $4,070,000 | – | 58,138 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |